The molecular basis of increased glomerulosclerosis after blockade of the renin angiotensin system in growth hormone transgenic mice.

Peten EP, Striker LJ, Fogo A, Ichikawa I, Patel A, Striker GE
Mol Med. 1994 1 (1): 104-15

PMID: 8790606 · PMCID: PMC2229921

BACKGROUND - Angiotensin converting enzyme inhibitor (ACEi) therapy delays the onset of renal failure in diabetic nephropathy and inhibits or delays the onset of proteinuria in several animal models.

MATERIALS AND METHODS - We examined this question using a transgenic model of chronic glomerulosclerosis caused by an excess production of growth hormone (GH) in which there is progressive glomerular scarring leading to uremia. In addition, since GH mice do not have systemic hypertension or an elevated glomerular filtration rate, we could address the question of whether ACEi or angiotensin II receptor antagonists (AII RA) had an effect on the development of glomerulosclerosis under these conditions. Since excess matrix accumulates in glomerulosclerosis because of alterations in the balance between its synthesis and degradation, we examined the effect of ACEi and AII RA on these parameters.

RESULTS - Systemic blood pressure was unaffected by ACEi treatment, but the glomerular filtration rate decreased 85%. ACEi-treated mice had increased mesangial deposition of type I collagen and decreased 105 kD complex collagenase activity. In addition, ACEi-treated GH mice had increased glomerular alpha 1 type I collagen, alpha 1 type IV collagen, and alpha-smooth muscle cell actin mRNAs. No changes were noted in beta actin, or 72 kD metalloproteinase mRNAs. The result of these changes was a net increase in sclerosis. Surprisingly, GH mice treated with ACEi or AngII RA developed marked renal arteriolar lesions.

CONCLUSIONS - In some forms of glomerulosclerosis, the lesions develop independently of angiotensin II. Pharmacological inhibition of angiotensin II, in this circumstance, may aggravate the lesions through disregulation of the levels and the balance between glomerular matrix synthesis and degradation.

MeSH Terms (33)

Actins Albuminuria Angiotensin-Converting Enzyme Inhibitors Angiotensin Receptor Antagonists Animals Base Sequence Blood Pressure Body Weight Captopril Collagen Collagenases Creatinine Disease Models, Animal Extracellular Matrix Gelatinases Glomerular Filtration Rate Glomerular Mesangium Glomerulosclerosis, Focal Segmental Growth Hormone Imidazoles Juxtaglomerular Apparatus Kidney Kidney Glomerulus Lymphotoxin-alpha Mice Mice, Transgenic Muscle, Smooth Organ Size Renin Renin-Angiotensin System RNA, Messenger Tetrazoles Thymidine

Connections (2)

This publication is referenced by other Labnodes entities: